We recently published our article Top 10 Healthcare Stocks to Buy With $1000 in 2026. In this piece, we take a closer look at Johnson & Johnson (NYSE:JNJ) to examine its latest developments, pipeline progress, and why it continues to draw attention from investors.

Healthcare stocks are once again moving higher on investors’ watchlists as Wall Street searches for opportunities beyond the usual technology and artificial intelligence leaders. The sector has traditionally been viewed as a defensive corner of the stock market, but in 2026, the healthcare investment story is becoming much broader.

The basic defensive argument remains easy to understand. Consumers can postpone buying a new phone, cancel a vacation or reduce discretionary spending during an economic slowdown, but they generally cannot simply stop purchasing essential medications or delay every necessary medical procedure. Healthcare demand tends to remain relatively resilient even during uncertain economic periods, making healthcare stocks attractive to investors looking for stability.

But stability is only part of the story.

Artificial intelligence, an aging U.S. population, rising healthcare spending, pharmaceutical innovation and booming demand for GLP-1 obesity drugs are creating significant long-term growth opportunities across the healthcare sector. According to projections cited by the Centers for Medicare and Medicaid Services, U.S. healthcare spending is expected to grow at an average annual rate of 5.4% through 2034.

That means trillions of dollars will continue flowing through pharmaceutical companies, healthcare providers, medical-device manufacturers, biotechnology companies, insurers and other businesses connected to the healthcare industry.

For investors looking for the best healthcare stocks to buy in 2026, the opportunity may increasingly come from companies combining defensive characteristics with strong long-term growth potential.

Aging Americans Could Keep Healthcare Demand Growing

One of healthcare’s biggest advantages is also one of its most predictable: demographics.

The baby boomer generation continues to age, creating increasing demand for medications, diagnostic testing, chronic disease management, medical devices and hospital procedures. Older populations typically consume significantly more healthcare services than younger populations, giving the industry a demographic tailwind that could last for years.

Unlike many Wall Street trends that appear suddenly and disappear just as quickly, population aging happens gradually and predictably.

That matters for long-term investors.

Healthcare companies positioned in areas such as oncology, cardiovascular disease, diabetes, obesity, immunology and other age-related conditions could continue benefiting as healthcare utilization expands.

Add rising medical spending and scientific innovation, and the best healthcare stocks for 2026 may offer considerably more growth potential than their reputation as merely defensive investments suggests.

GLP-1 Drugs Have Changed the Healthcare Investment Story

Few pharmaceutical developments have attracted as much investor attention in recent years as GLP-1 medications.

Originally associated primarily with diabetes treatment, GLP-1 drugs have rapidly expanded into the obesity market, creating what could eventually become one of the largest pharmaceutical opportunities in the world.

The market is enormous.

Millions of patients potentially qualify for obesity or diabetes treatments, and pharmaceutical companies are racing to develop newer drugs that could deliver better results, easier dosing or fewer side effects.

For investors searching for pharmaceutical stocks to buy, obesity drugs have therefore become one of the most important healthcare growth themes to watch.

But the opportunity extends beyond whichever company currently sells the most popular treatment. Investors must also consider drug pipelines, manufacturing capacity, competition, regulatory approvals and potential expansion into additional medical conditions.

In other words, the GLP-1 story is only beginning to develop.

Artificial Intelligence Could Become Healthcare’s Next Major Catalyst

Artificial intelligence is another potentially powerful tailwind for healthcare stocks.

Most of the AI investment boom has centered on semiconductor companies, cloud computing providers and major technology stocks, but healthcare could become one of the technology’s most important real-world applications.

Pharmaceutical companies are increasingly exploring artificial intelligence for drug discovery and clinical research. Healthcare systems can use AI to analyze patient information, streamline administrative work and improve diagnostic processes. Medical-device companies are also integrating software and advanced data analysis into their products.

Drug development remains expensive, time-consuming and risky, but even modest improvements in research efficiency could have enormous financial consequences for pharmaceutical companies.

That creates an interesting opportunity for investors looking for AI stocks outside traditional Big Tech.

Some established healthcare companies may ultimately benefit from artificial intelligence without carrying the same lofty valuations associated with many technology stocks.

Undervalued Healthcare Stocks Could Offer the Bigger Opportunity

Healthcare stocks are not automatically attractive simply because the sector is defensive.

Valuation still matters.

Pharmaceutical companies face patent expirations. Biotechnology companies can suffer major setbacks when clinical trials fail. Health insurers can experience unexpectedly high medical costs. Medical-device companies can face pricing pressure and changing demand.

Those risks are real, but they can also create investment opportunities.

When Wall Street becomes overly focused on temporary problems, strong healthcare companies can sometimes trade at valuations that underestimate their long-term earnings potential.

That is why some of the best healthcare stocks to buy are not necessarily the stocks receiving the most attention.

A company can experience slowing growth, disappointing earnings or uncertainty surrounding a major product and still remain fundamentally strong. If investors become too pessimistic, the stock can potentially become undervalued.

For value investors, that difference between market expectations and long-term fundamentals is where opportunities can emerge.

Pharmaceutical Stocks Offer More Than One Blockbuster Drug

Large pharmaceutical companies are also becoming increasingly diversified.

Many major drugmakers now operate across oncology, immunology, neuroscience, cardiovascular medicine, diabetes, obesity and rare diseases. Strategic acquisitions can strengthen those portfolios even further by adding promising treatments and expanding drug pipelines.

That diversification matters because one of the biggest risks facing pharmaceutical stocks is dependence on a small number of blockbuster products.

Eventually, patents expire.

Competition arrives.

Revenue can decline.

Companies with deeper pipelines and broader product portfolios may be better positioned to replace aging franchises and maintain long-term growth.

Strategic acquisitions have therefore become a critical part of the healthcare investment landscape. A well-timed acquisition can give a pharmaceutical company access to promising treatments and new markets, although expensive deals can also create risks when expected products fail to deliver.

For investors evaluating the best pharmaceutical stocks for 2026, management’s ability to allocate capital effectively may be almost as important as the drugs already on pharmacy shelves.

Healthcare Could Offer Both Defense and Growth

Perhaps the most interesting feature of healthcare investing in 2026 is the possibility of getting defensive characteristics and growth potential from the same sector.

Healthcare historically performs an essential economic function regardless of whether consumer confidence is rising or falling. At the same time, major innovations in obesity treatment, cancer medicine, medical technology and artificial intelligence could create new growth opportunities.

That combination is relatively unusual.

Technology stocks can deliver tremendous growth but often trade at demanding valuations. Traditional defensive stocks may provide stability but sometimes offer limited expansion potential.

Selected healthcare companies could sit somewhere between those two categories.

Many established pharmaceutical and healthcare companies also generate substantial cash flow and pay dividends, giving investors another potential source of return while waiting for new products, earnings growth or improved market sentiment.

For investors searching for defensive stocks, undervalued stocks, dividend stocks or long-term growth investments, healthcare could therefore deserve a closer look in 2026.

Why Analysts See Opportunity in Healthcare Stocks

CFRA analysts have identified several healthcare stocks they believe offer attractive upside potential in 2026.

The selections reflect a broader investment thesis that some healthcare companies may currently be valued too pessimistically relative to their future earnings potential, product pipelines and market opportunities.

Of course, healthcare investing comes with risks.

Clinical trials can fail. Regulators can reject drugs. Patent expirations can reduce revenue. Medical costs can increase. Competition can intensify quickly.

But those uncertainties are precisely what can create attractive entry points when high-quality companies fall out of favor with investors.

The key is separating companies facing temporary challenges from businesses suffering permanent deterioration.

That distinction becomes especially important when searching for undervalued healthcare stocks.

The Search for the Best Healthcare Stocks to Buy in 2026

Investors should also remember one important Wall Street lesson: a great company is not automatically a great stock at every price.

Valuation, earnings expectations, product pipelines, competitive advantages and financial strength all matter.

The best healthcare stocks to buy in 2026 may therefore include both well-known pharmaceutical giants and companies that have recently fallen out of favor with investors.

Some could benefit from rising demand for obesity drugs. Others may gain from aging demographics, strategic acquisitions, healthcare spending growth or medical innovation.

Taken together, these trends make healthcare one of the more interesting sectors to watch in 2026.

The industry remains defensive enough to attract investors worried about economic uncertainty, yet innovative enough to participate in some of the biggest long-term trends shaping modern medicine.

The following countdown examines 10 healthcare stocks that CFRA analysts believe deserve attention in 2026, including several undervalued healthcare stocks with potentially meaningful upside.

From pharmaceutical leaders and medical innovators to companies positioned around some of the fastest-growing areas of healthcare, these names show why investors searching for the best healthcare stocks to buy may want to look beyond the market’s most crowded technology trades.

CHECK THIS OUT: 10 Biotech Stocks to Buy Now as Novo Nordisk (NVO) Shakes Up the $100B Weight-Loss Market and 10 Biotech Stocks That Could Turn Medicine Into Wall Street’s Next Gold Rush.

Our Methodology

Our ranking of the 10 best healthcare stocks to buy for 2026 is based on CFRA analyst recommendations, factoring in upside potential, valuation, financial strength, growth prospects, product pipelines and long-term industry catalysts.

Top 10 Healthcare Stocks to Buy With $1000 in 2026

6. Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE: JNJ) ranks sixth, backed by one of the most recognizable names in global healthcare and a business increasingly focused on pharmaceuticals and medical technology.

After generations of consumers associated the company with everyday healthcare products, Johnson & Johnson (NYSE: JNJ) has evolved into a much more concentrated healthcare enterprise. Its investment story now revolves primarily around Innovative Medicine and MedTech, giving the company exposure to cancer treatments, immunology, medical devices and other higher-value areas of healthcare.

Among its important pharmaceutical products are Darzalex, a major treatment in multiple myeloma; Tremfya, which is used for inflammatory conditions including psoriasis and Crohn’s disease; and Rybrevant, an oncology medicine.

Tremfya has become especially important.

CFRA analyst Sel Hardy says the drug is delivering exceptional growth and helping Johnson & Johnson (NYSE: JNJ) absorb pressure from older immunology products Stelara and Remicade. Both of those established medicines are facing increasing competition, illustrating one of the perpetual challenges facing large pharmaceutical companies: today’s blockbuster eventually becomes tomorrow’s patent-expiration problem.

Successful pharmaceutical companies therefore have to continuously replace yesterday’s winners.

Johnson & Johnson (NYSE: JNJ) appears to have several opportunities to do exactly that. Its Innovative Medicine business contains commercial products and pipeline candidates that could support the next stage of growth, while the company’s restructuring strategy is designed to sharpen management’s attention on areas with greater long-term potential.

Hardy also views the planned strategic separation of the orthopedics business as a positive development. The logic is straightforward: a more focused Johnson & Johnson (NYSE: JNJ) could allocate capital and management resources toward higher-growth markets instead of carrying businesses with different growth profiles under the same structure.

That kind of portfolio simplification has become increasingly common across large healthcare companies as management teams attempt to convince investors that bigger is not always better unless the pieces fit together strategically.

CFRA has a “buy” rating and a $290 price target for Johnson & Johnson (NYSE: JNJ), compared with its July 30 closing price of $255.82. That suggests approximately 13% upside based on the supplied figures.

For investors searching for the best healthcare stocks to buy in 2026, Johnson & Johnson (NYSE: JNJ) offers an interesting middle ground. It has the scale and diversification expected from a defensive blue-chip healthcare stock, but it also has exposure to faster-growing pharmaceutical and medical technology markets.

That combination gives Johnson & Johnson (NYSE: JNJ) something many companies cannot easily replicate: defensive characteristics, enormous research resources and several potential paths toward future growth.

YOU MUST READ THIS: 10 Best Medicine Stocks That Could Make Investors 100% Richer

Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.